X

pharmaceuticals

Caplin Point Laboratories Ltd. (NSE: CAPLIPOINT): Q3FY23 Results Out; Total Income rise 15% YoY

Caplin Point Laboratories Ltd. (NSE: CAPLIPOINT) is a pharmaceutical company based in India. It is engaged in the development, manufacture,…

Shilpa Medicare Ltd (SHILPAMED) Q3 FY23 Earnings Concall Transcript

Shilpa Medicare Ltd (NSE: SHILPAMED) Q3 FY23 Earnings Concall dated Feb. 15, 2023 Corporate Participants: Vishnukanth Bhutada -- Managing Director Alpesh Dalal -- Chief…

Biocon Limited (BIOCON) Q3 FY23 Earnings Concall Transcript

Biocon Limited (NSE:BIOCON) Q3 FY23 Earnings Concall dated Feb. 15, 2023. Corporate Participants: Saurabh Paliwal -- Head - Investor Relations Kiran Mazumdar…

Marksans Pharma Limited Q3 FY23 Earnings Conference Call Insights

Key highlights from Marksans Pharma Limited (MARKSANS) Q3 FY23 Earnings Concall Q&A Highlights: [00:08:54] Riddhesh Gandhi from Discovery Capital asked…

Earnings Summary Of Granules India Limited For Q3 FY23

Granules India Limited (NSE: GRANULES) is a pharmaceutical manufacturing company based in Hyderabad, India. The company was founded in 1984…

Marksans Pharma Limited (MARKSANS) Q3 FY23 Earnings Concall Transcript

Marksans Pharma Limited (NSE:MARKSANS) Q3 FY23 Earnings Concall dated Feb. 14, 2023. Corporate Participants: Mark Saldanha -- Managing Director and Chief Executive…

Biocon ltd.(NSE: BIOCON) Ltd. : Q3 FY23 Results Out; Total Income rise 35% YoY

Biocon Limited (NSE:BIOCON) is an Indian multinational biopharmaceutical company based in Bangalore, India. The company was founded in 1978 by…

Brooks Laboratories Ltd.(NSE: BROOKS) Ltd. : Q3 FY23 Results Out; Total Income fell 20% YoY

Brooks Laboratories Limited (NSE: BROOKS) is a pharmaceutical contract research and manufacturing services company based in India. It offers a…

Themis Medicare Ltd (THEMISMED) Q3 FY23 Earnings Concall Transcript

Themis Medicare Ltd (NSE:THEMISMED) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Sachin D. Patel -- Managing Director and Chief…

Ipca Laboratories Limited Q3 FY23; Revenue Increased To ₹1,546 Crore

Ipca Laboratories Limited (NSE: IPCALAB) reported Revenue from Operations for Q3 FY23 of ₹1,546 Crore up from ₹1,430.47 Crore year…